We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome Patients Treated for Up to 3 Years.’ (ABSTRACT NUMBER: 978) was presented at the virtual AES 2020, 4-8 December 2020.
Questions
- What are the advantages of fenfluramine compared with other anticonvulsants in patients with Dravet syndrome? (1:18)
- What clinical evidence led to the regulatory approval of fenfluramine in patients with Dravet syndrome? (1:58)
- What have the findings of the extension study taught us about the long term efficacy and safety of fenfluramine in patients with Dravet syndrome? (2:39)
- What safety issues should be considered when prescribing fenfluramine? (3:43)
- Which patients are likely to benefit most from fenfluramine and in whom is it contraindicated? (4:34)
Disclosures: Ingrid Scheffer has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AES 2020, 4-8 December, 2020 (Virtual).
